Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities
-
By
-
Lidetian Hu
-
Haixing Cao
-
Yujie Zhang
-
Xiang Ma
-
July 15, 2026
Clinical Scorecard: Exploring Post-Translational Modifications in Retinoblastoma: Mechanisms, Immune Interactions, and Potential Treatment Strategies
At a Glance
| Category | Detail |
|---|
| Condition | Retinoblastoma |
| Key Mechanisms | Post-translational modifications (PTMs) affecting RB-centered signaling, chromatin regulation, and immune modulation. |
| Target Population | Pediatric patients with retinoblastoma. |
| Care Setting | Oncology with a focus on ocular safety and local drug delivery. |
Key Highlights
- PTMs are biologically relevant in retinoblastoma and require clinical prioritization.
- Therapeutic strategies must consider ocular safety and developmental implications.
- Targeted protein degraders and immunotherapy are emerging treatment strategies.
- Current therapies include ophthalmic artery chemotherapy and intravitreal chemotherapy.
- Local safety must be evaluated alongside antitumor activity.
Guideline-Based Recommendations
Diagnosis
- Evaluate PTM-related pathways in retinoblastoma for potential therapeutic targets.
Management
- Prioritize tumor-selective dependencies and ocular pharmacokinetics in treatment strategies.
Monitoring & Follow-up
- Assess ocular toxicity and complications from therapies such as intravitreal chemotherapy.
Risks
- Consider risks of retinal toxicity, cataract, and vitreous hemorrhage in treatment planning.
Patient & Prescribing Data
Pediatric patients diagnosed with retinoblastoma.
Therapies should be tailored to ensure ocular safety and effective local delivery.
Clinical Best Practices
- Validate PTM observations in human tumor models before clinical application.
- Ensure compatibility of new therapies with existing treatment routes.
- Evaluate immune modulation strategies specifically in retinoblastoma contexts.
Related Resources & Content
